Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Ritz

Showing results (171-180 of 315) with videos related to

Pageof 32
Sort By:
Nature|August 30, 2023
Epitope editing enables targeted immunotherapy of acute myeloid leukaemiaGabriele Casirati, Andrea Cosentino, Adele Mucci, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2009
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantationVincent T Ho, Matthew Vanneman, Haesook Kim, et al.
Cancer Research|February 4, 2010
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigensOvidiu Marina, Ursula Hainz, Melinda A Biernacki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2010
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia ReactionJeffrey S Miller, Edus H Warren, Marcel R M van den Brink, et al.
Blood|September 1, 2005
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaJohn G Gribben, David Zahrieh, Katherine Stephans, et al.
Blood Advances|January 4, 2018
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCTVincent T Ho, Haesook T Kim, Natalie Bavli, et al.
American Journal of Hematology|June 13, 2025
Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host DISAESE Prophylaxis in Patients With MyelofibrosisHaesook T Kim, Deborah J Liney, Kristen Rizza, et al.
Cancer Immunology Research|October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune ResponsesXia Bu, Vikram R Juneja, Carol G Reynolds, et al.
Blood Advances|August 21, 2023
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host diseaseHolly Wobma, Malika Kapadia, Haesook T Kim, et al.
Haematologica|August 26, 2021
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformationHaesook T Kim, Peter O Baker, Erin Parry, et al.
Pageof 32

Showing results (171-180 of 315) with videos related to

Sort By:
Pageof 32
Nature|August 30, 2023
Epitope editing enables targeted immunotherapy of acute myeloid leukaemiaGabriele Casirati, Andrea Cosentino, Adele Mucci, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2009
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantationVincent T Ho, Matthew Vanneman, Haesook Kim, et al.
Cancer Research|February 4, 2010
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigensOvidiu Marina, Ursula Hainz, Melinda A Biernacki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2010
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia ReactionJeffrey S Miller, Edus H Warren, Marcel R M van den Brink, et al.
Blood|September 1, 2005
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaJohn G Gribben, David Zahrieh, Katherine Stephans, et al.
Blood Advances|January 4, 2018
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCTVincent T Ho, Haesook T Kim, Natalie Bavli, et al.
American Journal of Hematology|June 13, 2025
Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host DISAESE Prophylaxis in Patients With MyelofibrosisHaesook T Kim, Deborah J Liney, Kristen Rizza, et al.
Cancer Immunology Research|October 12, 2021
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune ResponsesXia Bu, Vikram R Juneja, Carol G Reynolds, et al.
Blood Advances|August 21, 2023
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host diseaseHolly Wobma, Malika Kapadia, Haesook T Kim, et al.
Haematologica|August 26, 2021
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformationHaesook T Kim, Peter O Baker, Erin Parry, et al.
Pageof 32